CYP2D6 metabolizes nearly 25% of clinically used drugs. Genetic polymorphisms cause large inter-individual variability in CYP2D6 enzyme activity and are currently used as biomarker to predict CYP2D6 metabolizer phenotype. Previously, we had identified a region 115 kb downstream of CYP2D6 as enhancer for CYP2D6, containing two completely linked single nucleotide polymorphisms (SNPs), rs133333 and rs5758550, associated with enhanced transcription. However, the enhancer effect on CYP2D6 expression, and the causative variant, remained to be ascertained. To characterize the CYP2D6 enhancer element, we applied chromatin conformation capture combined with the next-generation sequencing (4C assays) and chromatin immunoprecipitation with P300 antibody, in HepG2 and human primary culture hepatocytes. The results confirmed the role of the previously identified enhancer region in CYP2D6 expression, expanding the number of candidate variants to three highly linked SNPs (rs133333, rs5758550 and rs4822082). Among these, only rs5758550 demonstrated regulating enhancer activity in a reporter gene assay. Use of clustered regularly interspaced short palindromic repeats mediated genome editing in HepG2 cells targeting suspected enhancer regions decreased CYP2D6 mRNA expression by 70%, only upon deletion of the rs5758550 region. These results demonstrate robust effects of both the enhancer element and SNP rs5758550 on CYP2D6 expression, supporting consideration of rs5758550 for CYP2D6 genotyping panels to yield more accurate phenotype prediction.
Introduction
CYP2D6 metabolizes nearly 25% of clinically used drugs. Its metabolic activity varies greatly between individuals, influencing dosing, efficacy and toxicity of CYP2D6-metabolized drugs (1) (2) (3) . It is one of the most polymorphic cytochrome P450s with over 100 allelic variants identified (http://www.imm.ki.se/CYPalleles). CYP2D6 genotype has robust effects on metabolizer phenotype and is listed in the US Food and Drug Administration's Table of Pharmacogenomics Biomarkers in Drug Labels (http://www.fda. gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ ucm083378.htm). Consequently, CYP2D6 genotype tests are currently used clinically to predict CYP2D6 metabolizer phenotypes, divided into poor, intermediate, extensive and ultra-rapid status. Moreover, to facilitate clinical translation, the Clinical Pharmacogenomics Consortium (CPIC) has published guidelines for CYP2D6/codeine and CYP2D6/tricyclic antidepressant gene/drug pairs (4) (5) (6) . However, uncertainty remains in predicting CYP2D6 phenotype from genotype using current genotyping panel. As reported in CPIC guidelines (4), individuals carrying two or only one fully active allele are all assigned the extensive metabolizer phenotype, with wide-ranging variability within genotype groups, suggesting additional polymorphisms yet to be discovered.
Recently, we have identified two completely linked single nucleotide polymorphisms (SNPs) (rs5758550 and rs133333) in an enhancer region located ∼115 kb downstream of CYP2D6 gene that are associated with >2-fold increased CYP2D6 transcription (7) . Moreover, CYP2D6*2 [rs16947, minor allele frequency (MAF) 17-48%], previously thought to convey normal activity, affects exon 6 splicing, thereby decreasing CYP2D6 expression at least 2-fold (7) . CYP2D6*2 is in high linkage disequilibrium (LD) with the new enhancer SNPs. Therefore, individuals carrying haplotypes that contain both *2 and the enhancer SNPs have CYP2D6 activity similar to the reference CYP2D6 haplotype; individuals carrying only *2 have reduced enzyme activity, while individuals carrying only enhancer SNPs have enhanced CYP2D6 enzyme activity (7) . A newly designed CYP2D6 SNPs panel that includes *2 and the enhancer SNPs predicted CYP2D6 phenotype more accurately in a pediatric cohort than the one listed in the CPIC guidelines (7).
Our previous study (7) did not address the question to what extent the downstream enhancer region regulates CYP2D6 expression, and it left open the question which of the two enhancer SNPs (rs5758550 and rs133333) are causative, or whether there are additional regulatory regions or SNPs. It is critical to identify the causative variants to study the biological mechanisms underlying the regulation of gene expression. In this study, we carried out chromatin conformation capture combined with high-throughput sequencing (4C assay) to search for any genomic regions that interact with the CYP2D6 promoter, with the goal of identifying DNA elements potentially affecting CYP2D6 expression. We also used reporter gene assays, chromatin accessibility assays, chromatin immunoprecipitation (ChIP) assays and clustered regularly interspaced short palindromic repeats (CRISPR)-mediated enhancer deletion to dissect the function of three highly linked SNPs (rs5758550, rs133333 and rs4822082) in the previously suspected enhancer region. Our results confirm the previously identified enhancer region as having robust effects on CYP2D6 expression and identify rs5758550 as the regulatory SNP further increasing CYP2D6 transcription. The study provides an example of detailed analysis of a distant enhancer variant with likely clinical relevance.
Results

Identification of possible enhancers for CYP2D6
To search for regions that interact with the CYP2D6 promoter, we performed 4C assays with the CYP2D6 promoter as an anchor.
Of all fragments mapped to chromosome 22, 60 were replicated in two independent experiments, and 35 of them with >100 sequence reads (2-fold genome-wide noise background, see 'Materials and Methods'). As shown in Figure 1A , the aligned 60 sequence fragments formed clusters within 300 kb up-or downstream of the CYP2D6 locus. Each cluster contains 3-15 positive signals, spanning ∼8-50 kb genomic area, consistent with a previous report (8) . Seven clusters with at least one signal >100 were identified (termed R1-R7). With the exception of R1 and R6, peak signals were all associated with an annotated gene locus (gene body, promoter or upstream region, R2, R3, R4, R5 and R7), suggesting cross-regulation between genes. R1 corresponds to the previously identified downstream enhancer region (7) , while R6 appears to be novel.
To test whether any of these regions could serve as an enhancer, we performed ChIP assays with an antibody against P300, a universal transcription co-factor that binds to enhancer elements. R1 and R2 displayed the highest signals in both HepG2 and hepatocytes (Fig. 1B and C) , consistent with R1 serving as an enhancer for CYP2D6, while R2 corresponds to the 3′ end of CYP2D6, indicative of active transcription of CYP2D6 in both cells. R6 showed low ChIP signals in both cells, arguing against an enhancer role. These results confirm the previously identified enhancer region (7) while failing to reveal additional robust regulatory regions for CYP2D6.
Functional characterization of variants inside the R1 region
Two completely linked SNPs rs133333 and rs5758550 inside the R1 enhancer region had been associated with increased CYP2D6 expression (7) . Using multiple primer pairs for realtime PCR to measure P300 ChIP signals, we found the highest ChIP signal located upstream of rs5758550 and downstream of another SNP rs4822082 (Fig. 2B) , which is also in high LD with rs5758550/rs133333 (D′ = 0.99, R 2 = 0.93). To test the effects of each SNP on enhancer activity, we performed reporter gene assays using different enhancer fragments (E1, E2 and E3; Fig. 3A ) joined to the CYP2D6 promoter. As shown in Figure 3B , fragment E1 increased luciferase activity of CYP2D6 promoter, consistent with previous results (7) . Constructs containing the minor allele rs5758550G had higher activity than the major allele rs5758550A, whereas constructs containing either the rs133333G or A allele together with the major allele rs5758550A had lower activity, indicating rs5758550G is the functional allele increasing CYP2D6 expression. Similarly, fragment E2 harboring the allele combination rs5758550G and minor allele rs4822082C had higher activity than rs5758550A/4822082T, while deletion of the region surrounding rs4822082 (fragment E3) did not affect the activity of rs5758550G, suggesting rs4822082 does not contribute to the effects observed with rs5758550G. Openness of chromatin measured by DNaseI accessibility is thought to be associated with the presence of regulatory elements (9, 10) , leading to the use of DNaseI hypersensitivity to search for regulatory regions or variants (11) . To determine the relative chromatin accessibility along the R1 region, we performed DNaseI accessibility assays in both HepG2 and primary human hepatocytes, followed by real-time PCR (12) . As expected, the region surrounding rs5758550 (A5) showed the highest accessibility in both cell types (Fig. 4) , consistent with its role as enhancer.
Deletion of the region surrounding rs5758550 using CRISPR system
To further test the in vivo enhancer effects on CYP2D6 mRNA expression, we deleted the region surrounding rs5758550 in HepG2 cells using CRISPR-cas in a lentivirus vector. As shown in Figure 5 , combining guide RNA g3 and g5 resulted in ∼70% deletion of the targeted 241 bp surrounding rs5758550 (see Supplementary Material, Fig. S1 ). This deletion also caused a ∼70% decrease in CYP2D6 mRNA levels. In contrast, other guide RNA combination (g3 + g6, g4 + g5 and g4 + g6) that failed to delete this region, or a negative control (g3 + g4) unable to delete this region, did not change CYP2D6 mRNA levels. Similar results were obtained in three repeat experiments (Supplementary Material, Fig. S2 ). In contrast, deletion of targeted 156 bp surrounding rs133333 (g1+g2) failed to change CYP2D6 mRNA level ( various haplotype/genotype combinations in HepG2 cells. Luciferase activities were measured at 48 h post-transfection and normalized to activity of the CYP2D6 promoter without enhancer. Expression plasmids without the promoter supported minimal transcription (<5% compared with plasmids with the CYP2D6 promoter). Data are mean ± SD, compared with promoter alone, *P < 0.05, **P < 0.01; compare with E1 with rs133333A/rs5758550A haplotype, ### P < 0.001, one-way ANOVA with Dunnett's post-test. Letters above the enhancer box indicate the genotype of rs133333 and rs5758550 for E1 or rs5758550 and rs4822082 for E2 or rs5758550 for E3.
Discussion
In this study, using 4C and ChIP assays, we confirm a previously identified enhancer region far downstream of CYP2D6 as the main regulatory element for CYP2D6 expression. Among three highly linked SNPs in this region, we identify rs5758550 as the causative variant that regulates enhancer activity, with the minor allele rs5758550G displaying higher activity than the major allele rs5758550A. Moreover, using CRISPR-mediated genomic deletion in HepG2 cells, we demonstrate that deletion of the enhancer region surrounding rs5758550 by 70% decreased CYP2D6 mRNA level >2-fold. As HepG2 cells are homozygous for the major allele rs5758550A, which is the lower expressing allele, this enhancer region exerts considerable influence on CYP2D6 expression. The minor allele rs5758550G further strengthens the enhancer activity of this region significantly, enhancing allelic CYP2D6 mRNA expression in the liver 2-to 4-fold (7). Large-scale databases further support an enhancer function of the region surrounding rs5758550; for example, a SNP even further downstream of rs5758550, namely rs8138080 (in high LD with rs5758550, D′ = 1, R 2 = 0.35), is associated with CYP2D6 mRNA levels in human livers (13, 14) ; however, rs8138080 is more frequent (33% MAF in Caucasian) than rs5758550 (24% MAF) and does not account for allelic CYP2D6 mRNA expression (7) . Therefore, rs8138080 only serves as a surrogate marker. In addition, data from the Genotype-Tissue Expression Project (GTEx) (http://www.gtexportal.org/home/) show that the minor allele rs5758550G is associated with higher CYP2D6 mRNA level in whole blood with the order of expression level GG > AG > AA for rs5758550 (P = 3.8 ×10 −9 , n = 168) (Supplementary Material, Fig. S4 ), indicating similar regulation of rs5758550 in the blood and in the liver. Because of small sample size of liver tissue (n = 32), the expression quantitative trait loci data are not currently available for liver tissues. Regulatory elements (enhancers, silencers, locus control regions, etc.) may be dispersed over tens to thousands of kilobases from the regulated genes (15,16), and 50% of genes engage in more than one long-range interaction (17) . To search for additional regulatory regions that may interact and regulate CYP2D6 expression, we performed 4C assays using the CYP2D6 promoter as an anchor. This approach yielded several strong interacting regions. Two of these (R1 and R6) are not directly associated with actively transcribed genes in the liver, but the low P300 ChIP signal inside the R6 region argues against an enhancer function. Other regions (R2-R5, R7) are upstream of transcribed genes, likely serving as a promoter or proximal enhancer for other genes, for example, CYP2D6, TCF20, NFAM1 and CYP2D7 pseudogene. Because all of these are actively transcribed in the liver, including the CYP2D7/8 pseudogenes, we propose that they share the same chromatin domain as CYP2D6, consistent with the finding that chromosomes divide into extended areas of active and inactive chromatin (8) . Possibly, genes in the CYP2D6 domain are under mutual regulation and not independent of each other. Genes in the same chromatin domain may share and compete for a common enhancer as reported previously (18) . As rs5758550 in the R1 region regulates CYP2D6 mRNA expression (7), it is possible that R1 also regulates the transcription of other genes particularly when CYP2D6 is deleted (for example, CYP2D6*5), as previously reported for adventitious up-regulation of NME4 in the absence of the α-globin gene (18) . Our results did not reveal additional variants in other regions accounting for allelic mRNA expression of CYP2D6, confirming the previously identified enhancer marked by rs5758550 as the main regulatory region.
We have previously demonstrated that haplotypes containing different combinations of rs16947 (coding SNP, *2) and enhancer SNPs rs133333/rs5758550 determine CYP2D6 mRNA expression and affect CYP2D6 enzyme activity in a pediatric cohort (7) . Even though these two sites are separated by >100 kb, they are in high LD with each other (D′ = 0.97, R 2 = 0.51 in European population). CYP2D6*2 conveys reduced enzyme activity because of a splicing defect but it is more frequent (MAF 40%) than enhancer SNP rs5758550 (MAF 24%). These relationships serve to predict CYP2D6 enzyme activity in carriers of either or both variants. CYP2D6*2 alleles lacking rs5758550 (rs16947T/rs5758550A) convey reduced activity, while *2 alleles with rs5758550 (rs16947 T/rs5758550G) display wild-type enzyme activity. A smaller number of CYP2D6 alleles carry only the rs5758550 enhancer variant (rs16947C/rs5758550G) and therefore convey increased activity (7) . Because the enhancer rs5758550 could reside on nonfunctional CYP2D6 haplotypes, we scanned the 1000 genome project for LD with null alleles. rs5758550 displays high D′ (0.93-1) but low R 2 (0-0.06) with the loss-of-function alleles rs3892097 (*4), rs35742686 (*3), rs5030656 (*6), rs1065852 (*10) or rs5030656 (*9), indicating rs5758550 is unlikely to be on the same haplotype. After exclusion of haplotypes also harboring *4, *3, *6, *10 or *9, the frequencies for haplotypes containing rs16947T/rs5758550A (reduced activity), rs16947T/rs5758550G (normal activity) or rs16947C/rs5758550G (enhanced activity) are 0.11, 0.22 and 0.01 in European population, and 0.25, 0.12 and 0.09 in African population, indicating significant impact of different combinations of *2 and rs5758550 on CYP2D6 activity in different ethnic groups. In view of the robust wild-type enhancer activity (rs5758550A) and additional 2-fold enhancement by rs5758550G, carriers of the minor allele rs5758550G alone (without *2 and other loss-offunction alleles) could be classified as ultra-rapid metabolizers, consistent with recommendations reflecting fully active CYP2D6 gene duplications (CYP2D6*1 × 2, activity score = 2) (6). The effects of rs5758550G on CYP2D6 mRNA expression may exceed CYP2D6 gene duplication containing two copies of CYP2D6*1, because in the case of gene duplication, the enhancer region is not duplicated; thus, only one copy of CYP2D6 can be regulated by the single enhancer, while the other gene copy might be expressed at a considerably lower level. The implications of these results require further testing in clinical studies before CYP2D6 biomarker assays can be modified.
In summary, we demonstrate robust effects of enhancer and rs5758550 on CYP2D6 mRNA expression. The incorporation of both CYP2D6*2 and enhancer SNP rs5758550 in current CYP2D6 genotyping panel as proposed previously (7) may result in better prediction of CYP2D6 enzyme activity.
Materials and Methods
Cell culture and transfection
Human primary hepatocytes culture (Hep4, Hep8, Hep10 and Hep11) were obtained from Liver Tissue Cell Distribution System (LTCDS, Pittsburgh, PA, USA), which was funded by NIH Contract # HHSN276201200017C. The demographic information of donors were as followed: Hep4, 50 years, male, metastatic cancer with chemotherapy, unknown racial status; Hep8, 31 years, Caucasian male, metastatic cancer with chemotherapy; Hep10, 31 years, female with benign liver tumor, unknown racial status; Hep11, 31 years, Caucasian female, benign tumor. Upon receiving the cells, the media were replaced with serum-free William's E media supplemented with penicillin/streptomycin/fungizone (100 U/100 µg/0.25 µg per ml), 100 n dexamethasone, 2 m -glutamine, 15 m [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] and 0.55 mg/ml human transferrin, 1 mg/ml bovine insulin and 0.5 µg/ml sodium selenite, from Sigma, and incubated at 37°C in a humidified incubator at 5% CO 2 . After 24 h, cells were used for 4C (Hep10), chromatin accessibility (Hep11) and ChIP (Hep4, Hep8 and Hep10) assays. HepG2 cells were cultured at 37°C in a humidified incubator at 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. The day before transfection, cells were plated into 12-well plates. Transfection was performed using lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA).
Chromatin conformation capture combined with high-throughput sequencing (4C assay)
Preparation of 4C template The 4C template for human primary hepatocytes was prepared as described (19) . Briefly, 10 million primary cultured human hepatocytes were detached with trypsin to obtain a single cell suspension. Then, cells were cross-linked with 2% formaldehyde for 10 min before lysing to release cell nuclei. Cell nuclei were digested with NlaIII at 37°C overnight followed by proximity ligation with T4 ligase after dilution over 20 times. After reverse cross-linking, the purified DNA was subjected to secondary digestion with DpnII, followed again by proximity ligation after dilution. The resulting DNA was purified by phenol/chloroform extraction.
PCR amplification of 4C template
Inverse primers were designed as described (20) . PCR was performed with inverse primers (Supplementary Material, Table S1 ) specific to the CYP2D6 promoter using 25 ng 4C templates and run for 25 cycles. A total of eight PCR reactions were performed and the PCR products were combined. To enrich PCR products, we labelled both primers with Biotin at 5′ end. The PCR products were purified and enriched with Streptavidin Magnetic Beads (Dynabeads MyOne Streptavidin C1, Invitrogen, Grand island, NY, USA) followed by digestion with NlaIII to release amplified fragments from the beads. Then, the reaction tubes were placed on a magnet for 1 min to remove the streptavidin beads and bound biotin-labelled primers. The supernatants were purified with Qiagen PCR purification kit. The DNA was sheared to 100-200 bp using S2/E210 Focused-Ultrasonicator (Covaris, Woburn, MA, USA) and subjected to Ion Torrent sequencing.
Ion Torrent sequencing
We used 100 ng DNA for Ion Torrent library preparation using NEBNext Fast DNA Library Preparation kit (New England BioLabs, Ipswich, MA, USA). After adaptor ligation, the DNA was purified with four columns of High Pure PCR Product Purification columns (Roche, Madison, WI, USA) to avoid adaptor dimer contamination. Then, adaptor-ligated library was PCR amplified for eight cycles followed by DNA purification with two columns of High Pure PCR Product Purification columns. The amplified library was diluted and subjected to emulsion PCR using Ion OneTouch 2 instrument (Life Technology, Grant Island, NY, USA). The resulting library was sequenced on Ion Torrent PGM using Ion PGM 200 Sequencing kit (Life Technology).
Analysis of sequencing data
The sequencing data were analyzed with CLC Genomics Workbench 4.8 (CLC bio, Denmark). To identify the peaks, we used ChIP-Seq analysis algorithm with a window size of 250 and a false discovery rate of 5%. Typically, we obtained ∼5000 peaks genome wide with median number of reads ∼50. Most of these fragments are likely be non-specific noise, either from random proximity ligation (21) or contamination from the 4C template. Because our goal is to identify cis-acting regulatory regions for CYP2D6, we focused our analysis on chromosome 22. To identify possible true interacting fragments, we selected only replicated signals from two independent experiments and focused on signals with >100 reads (2-fold genome-wide noise background).
ChIP assays
ChIP assay was performed in HepG2 cells and human primary hepatocytes using ChIP-IT Express Enzymatic kit (Active Motif, Carlsbad, CA, USA) with anti-P300 antibody (Active Motif ). The enrichment of DNA fragments with P300 antibody was measured by real-time PCR using SYBR Green and specific primers (Supplementary Material, Table S1 ), and compared with negative control without P300 antibody. Multiple primer pairs were designed for each test region (10 kb surrounding highest 4C signal), and results with highest enrichments are shown.
Chromatin accessibility assays
Chromatin accessibility measured by real-time PCR (CHART-PCR) was performed as described (12) . Briefly, one million cells (HepG2 and human hepatocytes) were lysed and nuclei prepared. Then nuclei were washed and treated with different concentrations of DNaseI for 3 min at 37°C. The DNA was purified by phenol/ chloroform, chloroform extraction and ethanol precipitation. Chromatin accessibility was measured by real-time PCR using different primer pairs (Supplementary Material, Table S1 ) that target at different locations. Chromatin accessibility was calculated as the ratio of (amount uncut DNA)/(amount cut DNA).
Reporter gene assays A previously used 4.3 kb CYP2D6 promoter in pGL3 (7) was digested with MluI and EcoRI, then treated with DNA polymerase I Klenow fragment to create blunt ends, followed by ligation to generate a shorter form CYP2D6 promoter construct (1.7 kb, 2581-4381 in AY545216). Then, the enhancer region fragments were amplified by PCR and joined to the 5′ end of CYP2D6 promoter (see Supplementary Material, Table S1 for primer sequence). Enhancers with different genotype combinations were either generated by PCR amplification from gDNA with the corresponding genotype/haplotype or by site-directed mutagenesis, which was carried out with the QuickChange lightning II kit (Agilent). All constructs were sequenced to ensure the absence of any random mutations during PCR amplification. To avoid variability from colonized bacterial clones, the plasmids were re-transformed into DH5α competent cells, and for each construct, three clones were selected for plasmid DNA preparation. Cells were transfected with 1 µg plasmid DNA and luciferase activity measured 48 h later with the Dual-Glo luciferase assay kit (Promega, Madison, WI, USA) on a Fusion Universal Microplate Analyzer (PerkinElmer Life and Analytical Science, Waltham, MA, USA). As internal control, Renilla luciferase constructs driven by a TK promoter were co-transfected with promoter constructs at 1 : 5 ratio.
Deletion of enhancer region using CRISPR-associated RNA-guided endonuclease Cas9
A lentiviral-based single vector (LentiCRISPR) that simultaneously deliver Cas9, single guide RNA (sgRNA) and puromycin selection marker engineered by the Zhang Laboratory (22) was purchased from Addgene (http://www.addgene.org/). Oligos (20 bp in length) corresponding to guide RNA sequence were designed using online tool (tools.genome-engineering.org; Supplementary Material, Table S1 ). Cloning of guide sequence into LentiCRISPR vector was performed according to protocol available from the Zhang Laboratory (www.genome-engineering.org). To produce lentivirus particles, 6 µg LentiCRISPR containing specific guide RNA sequence was co-transfected with 3 µg pvSVg (Addgene) and 4.5 µg psPAX2 (Addgene) into HEK-T cells in 10 cm dishes using Lipofectamine 2000 (Life Technologies). After 60 h, the supernatant was harvested and concentrated 50-fold with Lenti-X Concentrator (Clontech). To find optimal virus volumes for achieving a multiplicity of infection (MOI) of 1, HepG2 cells in 24-well plate were transduced with different volumes (5-40 µl) of virus particles overnight. Then, cells were detached with trypsin, counted and split into duplicate wells. One replicate received 1 µg/ml puromycin (Sigma), and one was untreated. After 3 days, cells were counted to calculate percent transduction. Untransfected cells did not survive treatment with 1 µg/ml puromycin for 3 days. Transduction of lentivirus particles into HepG2 cells were performed using SureENTRY transduction reagent (SABiosciences). Deleting a genome region requires two guide RNAs that target separate genome locations to generate two double strand breaks simultaneously. Lentivirus particles with two different guide RNA were co-transduced at higher titer (1 × MOI for each) into HepG2 cells, then cells were selected with higher concentration of puromycin (2 µg/ml) for 3 days to ensure at least two virus particles enter each cell. Cells were divided into two wells (for gDNA and RNA preparations, respectively), and cultured to 70-80% confluence. Genomic DNA and total RNA were prepared using Quick gDNA or RNA minipres kits (Zymos). Deletion of targeted regions was determined with PCR amplification using fluorescently labeled primer (Supplementary Material, Table S1 ) followed by separation on an ABI3730 capillary sequencer as described previously for splice variant genotyping (23) .
CYP2D6 total mRNA quantification
Total CYP2D6 mRNA was measured using real-time PCR with specific primers (Supplementary Material, Table S1 ) and SYBR Green PCR master mix (Life Technologies) using β-actin as internal control (7) .
Data analysis
Data are expressed as mean ± SD. Statistical analysis was performed using Prism (GraphPad Software, San Diego, CA, USA).
Supplementary Material
Supplementary Material is available at HMG online.
